Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma
August 24, 2021 07:00 AM Eastern Daylight Time Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical…
Melanoma Research
08/25/2021
Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma
August 24, 2021 07:00 AM Eastern Daylight Time Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical…
|
|
07/22/2021
FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin
July 21, 2021 (repost) Sara Karlovitch The FDA has granted an orphan drug designation to alrizomadlin, an MDM2-p53 inhibitor, for…
|
|
07/12/2021
Gut Microbes Signal Response to Immune Therapy in Melanoma
(re-post from original article in GEN News) Programmed cell death protein 1 (PD-1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) are…
|
|
06/30/2021
EORTC and Pierre Fabre Partner to Address Treatment Gap for Stage II Melanoma Patients
Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage II melanoma patients EUROPEAN ORGANISATION…
|
|
06/15/2021
Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma
June 14, 2021 08:03 AM Eastern Daylight Time | Source: Business Wire DURHAM, N.C.–(BUSINESS WIRE)–Istari Oncology, Inc., a clinical-stage biotechnology…
|
|
06/04/2021
Alkermes’s disappointment hones melanoma niche focus
June 04, 2021 | Source: Madeleine Armstrong, Evaluate Vantage Alkermes plays up responses in mucosal melanoma, but those hoping for…
|
|
05/21/2021
Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma
PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced new six-and-a-half-year data from CheckMate -067, a randomized, double-blind, Phase 3…
|
|
04/15/2021
Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma
Published: April 10, 2021, Kristi Rosa in Targeted Oncology In patients with metastatic uveal melanoma, frontline treatment with tebentafusp…
|
|
04/14/2021
Lifileucel Proves Efficacy in Pretreated Advanced Melanoma
Published: April 12, 2021, Lisa Astor in Oncology Nursing News Lifileucel produced durable responses in advanced melanoma that was previously…
|
|
03/11/2021
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
March 11, 2021 | Source: PRNewswire DUBLIN, March 11, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced…
|
|
Recent Posts
Oct. 17, 2024
In Plain English: Update on Melanoma Vaccines, 2024
Oct. 15, 2024
Options For Stage II Melanoma: Making the Decision that’s Right For You
Oct. 10, 2024
Coolibar’s Generous Donation to the AIM at Melanoma Foundation
Oct. 10, 2024
Fall 2024 Newsletter
Oct. 10, 2024